27697751|t|MiR-495 functions as an adjuvant to radiation therapy by reducing the radiation-induced bystander effect
27697751|a|The radiation-induced bystander effect (RIBE) is an important factor in tumor radiation therapy because it may increase the probability of normal cellular injury and the likelihood of secondary cancers after radiotherapy. Here, we identified the role of miR-495 in alleviating RIBEs during radiotherapy. Luciferase reporter assay results confirmed that miR-495 regulated endothelial nitric oxide synthase (eNOS) by targeting the Sp1 3'-untranslated region. Consequently, after radiation, tumor cells expressed less eNOS and Sp1 than controls. In vitro cell irradiation data based on flow-cytometric analysis and enzymed linked immunosorbent assay confirmed that nitric oxide (NO) and its downstream product transforming growth factor β1 (TGF-β1) were critical signaling factors contributing to RIBEs. Fewer normal LO2 liver cells were injured and fewer micronuclei were observed when treated with the medium of the miR-495 overexpressing HepG2 and ZR75-1 tumor cells. Accordingly, treatment with the miR-495 antagomir led to higher NO and TGF-β1 levels and more injured LO2 cells. In vivo experiments indicated that local irradiation of tumors overexpressing miR-495 produced fewer necrotic foci in non-irradiated liver tissue compared with controls. miR-495 was upregulated in clinical cancer tissues compared with adjacent non-cancerous tissues, and radiation significantly reduced the expression level of miR-495 in carcinoma cell lines. In summary, miR-495 may have promise as an adjuvant for tumor radiation therapy to decrease RIBEs involving the Sp1 / eNOS pathway.
27697751	0	7	MiR-495	T028	C1826049
27697751	8	17	functions	T045	C0314627
27697751	24	32	adjuvant	T169	C1522673
27697751	36	53	radiation therapy	T061	C1522449
27697751	57	65	reducing	T080	C0392756
27697751	70	104	radiation-induced bystander effect	T043	C0949629
27697751	109	143	radiation-induced bystander effect	T043	C0949629
27697751	145	149	RIBE	T043	C0949629
27697751	157	166	important	T080	C3898777
27697751	167	173	factor	T169	C1521761
27697751	177	182	tumor	T191	C0027651
27697751	183	200	radiation therapy	T061	C1522449
27697751	216	224	increase	T169	C0442805
27697751	229	240	probability	T081	C0033204
27697751	244	266	normal cellular injury	T049	C0599732
27697751	275	285	likelihood	T081	C0033204
27697751	289	306	secondary cancers	T191	C0027627
27697751	313	325	radiotherapy	T061	C1522449
27697751	336	346	identified	T080	C0205396
27697751	351	355	role	T077	C1705810
27697751	359	366	miR-495	T028	C1826049
27697751	382	387	RIBEs	T043	C0949629
27697751	395	407	radiotherapy	T061	C1522449
27697751	409	434	Luciferase reporter assay	T059	C0005507
27697751	435	442	results	T034	C1254595
27697751	443	452	confirmed	T033	C0750484
27697751	458	465	miR-495	T028	C1826049
27697751	476	509	endothelial nitric oxide synthase	T116,T126	C0669365
27697751	511	515	eNOS	T116,T126	C0669365
27697751	520	529	targeting	T169	C1521840
27697751	534	537	Sp1	T116,T123	C0080245
27697751	538	560	3'-untranslated region	T086,T123	C0600600
27697751	582	591	radiation	T070	C0851346
27697751	593	604	tumor cells	T025	C0597032
27697751	605	614	expressed	T045	C1171362
27697751	620	624	eNOS	T116,T126	C0669365
27697751	629	632	Sp1	T116,T123	C0080245
27697751	638	646	controls	T096	C0009932
27697751	648	656	In vitro	T080	C1533691
27697751	657	678	cell irradiation data	T078	C1511726
27697751	688	712	flow-cytometric analysis	T062	C0936012
27697751	717	751	enzymed linked immunosorbent assay	T059	C0014441
27697751	752	761	confirmed	T033	C0750484
27697751	767	779	nitric oxide	T121,T123,T197	C0028128
27697751	781	783	NO	T121,T123,T197	C0028128
27697751	793	803	downstream	T082	C0522506
27697751	804	811	product	T071	C1514468
27697751	812	841	transforming growth factor β1	T116,T121,T123	C1704256
27697751	843	849	TGF-β1	T116,T121,T123	C1704256
27697751	856	864	critical	T080	C1511545
27697751	865	874	signaling	T038	C3537152
27697751	875	882	factors	T169	C1521761
27697751	883	895	contributing	T052	C1880177
27697751	899	904	RIBEs	T043	C0949629
27697751	906	911	Fewer	T081	C0205388
27697751	919	934	LO2 liver cells	T025	C0227525
27697751	940	947	injured	T169	C0332664
27697751	952	957	fewer	T081	C0205388
27697751	958	969	micronuclei	T033	C0026004
27697751	975	983	observed	T169	C1441672
27697751	989	996	treated	T169	C1522326
27697751	1006	1012	medium	T167	C1705217
27697751	1020	1027	miR-495	T028	C1826049
27697751	1028	1042	overexpressing	T045	C0017262
27697751	1043	1048	HepG2	T025	C2717940
27697751	1053	1059	ZR75-1	T025	C0007634
27697751	1060	1071	tumor cells	T025	C0597032
27697751	1086	1095	treatment	T061	C0087111
27697751	1105	1112	miR-495	T028	C1826049
27697751	1113	1122	antagomir	T114	C4277666
27697751	1130	1136	higher	T080	C0205250
27697751	1137	1139	NO	T121,T123,T197	C0028128
27697751	1144	1150	TGF-β1	T116,T121,T123	C1704256
27697751	1151	1157	levels	T080	C0441889
27697751	1167	1174	injured	T169	C0332664
27697751	1175	1184	LO2 cells	T025	C0227525
27697751	1186	1193	In vivo	T082	C1515655
27697751	1194	1205	experiments	T062	C0681814
27697751	1206	1215	indicated	T033	C1444656
27697751	1221	1238	local irradiation	T070	C0851346
27697751	1242	1248	tumors	T191	C0027651
27697751	1249	1263	overexpressing	T045	C0017262
27697751	1264	1271	miR-495	T028	C1826049
27697751	1281	1286	fewer	T081	C0205388
27697751	1287	1300	necrotic foci	T046	C0333504
27697751	1304	1331	non-irradiated liver tissue	T023	C0736268
27697751	1332	1340	compared	T052	C1707455
27697751	1346	1354	controls	T096	C0009932
27697751	1356	1363	miR-495	T028	C1826049
27697751	1368	1379	upregulated	T044	C0041904
27697751	1383	1391	clinical	T080	C0205210
27697751	1392	1398	cancer	T191	C0006826
27697751	1399	1406	tissues	T024	C0040300
27697751	1407	1415	compared	T052	C1707455
27697751	1421	1429	adjacent	T082	C0205117
27697751	1430	1451	non-cancerous tissues	T024	C0040300
27697751	1457	1466	radiation	T070	C0851346
27697751	1467	1488	significantly reduced	T080	C0392756
27697751	1493	1509	expression level	T081	C3244092
27697751	1513	1520	miR-495	T028	C1826049
27697751	1524	1544	carcinoma cell lines	T025	C0596890
27697751	1549	1556	summary	T170	C1706244
27697751	1558	1565	miR-495	T028	C1826049
27697751	1575	1582	promise	T078	C1555307
27697751	1589	1597	adjuvant	T169	C1522673
27697751	1602	1607	tumor	T191	C0027651
27697751	1608	1625	radiation therapy	T061	C1522449
27697751	1629	1637	decrease	T081	C0547047
27697751	1638	1643	RIBEs	T043	C0949629
27697751	1658	1661	Sp1	T116,T123	C0080245
27697751	1664	1668	eNOS	T116,T126	C0669365
27697751	1669	1676	pathway	T044	C1704259